Adjuvant nivolumab plus chemoradiotherapy “could be proposed as a new standard treatment,” said Jean Bourhis, MD, PhD.

A retrospective, real-world data analysis from the TriNetX database sought to determine rates of venous thromboembolism and survival outcomes in patients with multiple myeloma who were treated with ...

A systematic review of the literature explored the impact of interventions on family dynamics in families of children with cancer.

There is a high unmet need for effective neoadjuvant treatments for muscle-invasive bladder cancer for patients who cannot tolerate or refuse cisplatin chemotherapy.

Investigators studied the effect of immunotherapy on overall survival among women with genital tract melanoma.

HealthDay News — For pediatric patients with retinoblastoma, aqueous humor liquid biopsy via anterior chamber paracentesis is a safe and well-tolerated procedure, according to a study recently ...

BSO not associated with increased risk for cardiovascular diseases, ischemic heart disease, or cerebrovascular disease.

Using the COMPASS model, researchers project risk of cardiac late effects for survivors of pediatric ALL at age 50 years.

Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

Various factors contribute to disparities in 30-day readmission rates following allogeneic hematopoietic stem cell transplantation (allo-HCT) among patients with acute myeloid leukemia (AML), ...

Rusfertide could be a new treatment option for patients with polycythemia vera, according to Andrew Kuykendall, MD.

Researchers sought to determine whether the ALL-Hematotox would be able to predict hematotoxicity for patients with B-ALL who are at risk of severe hematotoxicity following CAR-T therapy.